Opioids, Opioid Use Disorder, & Overdose Prevention

This updated 2022 vignette provides examples of how a range of Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) cross-agency projects are working to address the opioid overdose crisis by 1) Improving Timeliness and Quality of Outcomes Data 2) Building Capacity for Collection of Patient-Reported Outcomes 3) Building Linkages to Address Co-Morbidities

This brief presents estimates of the number and percentage of children whose parents engage in problematic substance use, including past-year substance use and SUD by substance type and child demographics. Key findings include:

Per Section 223(d)(7)(A) of the Protecting Access to Medicare Act (PAMA) of 2014 (Public Law 113-93), the HHS Secretary must submit to Congress an annual report on the use of funds provided under all demonstration programs conducted under this subsection, not later than one year after the date on which the first state is selected for a demonstration program under this subsection, and annually t

The COVID-19 pandemic had wide-ranging impacts on health care delivery, particularly services that require in-person interactions. For patients needing access to medications to treat pain or certain substance use disorders, the COVID-19 pandemic presented particular challenges for continuity of treatment.

Opioid use was very common among the long-term care (LTC) residents in our sample. Perhaps reflecting their post-acute rehabilitative needs, discharged residents were more likely to have opioid use prior to LTC admission and at the beginning of the LTC stay.

This report aims to address the treatment care models for pregnant and postpartum women with SUD by describing opportunities to integrate OB/GYN and SUD care as well as barriers to integrated care delivery.Related Products:

This brief highlights specific policy challenges and opportunities for policymakers to expand access to integrated services for pregnant and postpartum women with SUD.Related Products:

From 1999 through 2019, there were more than 840,000 drug overdose deaths in the United States. The crisis has continually evolved and escalated, including during the COVID-19 pandemic, when an estimated 93,000 persons lost their lives to drug overdose in 2020--approximately a 30% increase over the year prior.

Buprenorphine treatment has been found to be an effective treatment for opioid use disorder (OUD). Child welfare systems have been partnering with treatment providers to increase access, yet little is known about its role in improving outcomes related to child maltreatment.

How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services